Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
Clinical Infectious Diseases · 30.04.2026 · 82 (4) · e735-e742
DOI: 10.1093/cid/ciag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 24.02.2026. Verfasst von Rachel V Denyer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Section, Washington VA Medical Center, Washington D.C., USA. Hauptthemen laut MEDLINE: Virus Activation, HIV Infections, Hepatitis B virus, Hepatitis B Antibodies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAAA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
One in 3 people with human immunodeficiency virus (HIV-1; PWH) are hepatitis B (HBV) core antibody positive (anti-HBc+) and surface antigen negative (HBsAg−) suggesting prior exposure. HBV reactivation can occur in this group if nucleos(t)ide reverse transcriptase inhibitor antiretrovirals (ARV) active against both HIV and HBV are stopped. We describe HBV reactivation in anti–HBc+/HBsAg− PWH following switch from ARV with HBV activity to ARV without HBV activity.
Methods
We identified an at-risk cohort of 5986 anti-HBc+ participants switched from HBV-active to non–HBV-active ARV on or before 31 December 2023 and HBsAg− on the most recent result preceding switch from 63 153 PWH in the Veterans Aging Cohort Study. We defined HBV reactivation as HBV DNA detection or HBsAg+ result at any time following switch. HBV-active ARV included lamivudine, emtricitabine, or tenofovir.
Results
Forty (0.67%) anti-HBc+/HBsAg− PWH experienced HBV reactivation after switch to non–HBV-active ARV, with median time to reactivation 8.9 months (interquartile range 5.5–26.7). The rate of HBV reactivation was 25.1 per 10 000 person-years (95% confidence interval [CI], 18.4–34.3). Prespecified subgroup analyses revealed higher rates per 10 000 person-years of HBV reactivation in those HBsAg+ in the remote past with no hepatitis B surface antibody positive (anti-HBs+) result (321; 95% CI, 120–855) versus subgroups never previously HBsAg+ or anti-HBs+ (38.0; 95% CI, 22.9–63.0), or anti-HBs+ but never HBsAg+ (17.4; 95% CI, 11.2–27.0).
Conclusions
Overall risk of HBV reactivation appears low after switch from HBV-active to non–HBV-active ARV among anti-HBc+ PWH with no prior HBsAg+. Our results inform provider-patient discussion about HBV reactivation risk when considering ARV switching.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Section, Washington VA Medical Center, Washington D.C., USA.
- School of Medicine and Health Sciences, The George Washington University, Washington D.C., USA.
- Research Department, VA Connecticut Healthcare System, West Haven, Connecticut, USA.
- Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Rachel V Denyer, Debra A Benator
Förderung
- NIH HHS
- NIAAA NIH HHS
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Denyer, R. V., Tate, J. P., Benator, D. A., Lim, J. K., & Weintrob, A. (2026). Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity. Clinical Infectious Diseases, 82(4), e735-e742. https://doi.org/10.1093/cid/ciag001
Vancouver
Denyer RV, Tate JP, Benator DA, Lim JK, Weintrob A. Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity. Clinical Infectious Diseases. 2026;82(4):e735-e742. doi:10.1093/cid/ciag001
BibTeX
@article{Denyer2026,
author = {Denyer, Rachel V and Tate, Janet P and Benator, Debra A and Lim, Joseph K and Weintrob, Amy},
title = {Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {4},
pages = {e735--e742},
doi = {10.1093/cid/ciag001}
}
EUVIMED